Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani(Stanford Medicine), Nathan Fowler(Repligen (United States)), Juthamas Sukbuntherng(Pharmacyclics (United States)), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Richard R. Furman(Cornell University), Raquel Izumi, Eric Hedrick(Florida Hospital Cancer Institute), Betty Chang(Rigel (United States)), Sara Rodríguez(Navarre Institute of Health Research), Ahmed Hamdy(Pharmacyclics (United States)), Joseph J. Buggy(Pharmacyclics (United States)), Thomas E. Boyd(University of Vermont), Sonali M. Smith(University of Chicago), Barbara Grant(University of Vermont), Kathryn S. Kolibaba(University of Vermont)
Cited by 1,115
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k